CG Oncology, Inc.CGONEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
CGON Q4 FY2025 Key Financial Metrics
Revenue
$2.3M
Gross Profit
N/A
Operating Profit
$-48.7M
Net Profit
$-41.3M
Gross Margin
N/A
Operating Margin
-2097.3%
Net Margin
-1779.0%
YoY Growth
409.2%
EPS
$-0.52
CG Oncology, Inc. Q4 FY2025 Financial Summary
CG Oncology, Inc. reported revenue of $2.3M (up 409.2% YoY) for Q4 FY2025, with a net profit of $-41.3M (down 29.9% YoY) (-1779.0% margin).
Key Financial Metrics
| Total Revenue | $2.3M |
|---|---|
| Net Profit | $-41.3M |
| Gross Margin | N/A |
| Operating Margin | -2097.3% |
| Report Period | Q4 FY2025 |
CG Oncology, Inc. Quarterly Revenue & Net Profit History
CG Oncology, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.3M | +409.2% | $-41.3M | -1779.0% |
| Q3 FY2025 | $1.7M | +3774.4% | $-43.8M | -2629.5% |
| Q2 FY2025 | $0 | — | $-41.4M | N/A |
| Q4 FY2024 | $456.0K | +45500.0% | $-31.8M | -6973.7% |
| Q1 FY2024 | $529.0K | +172.7% | $-16.9M | -3200.8% |
Income Statement
| Q1 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Revenue | $529000 | $456000 | $0 | $1.7M | $2.3M |
| YoY Growth | 172.7% | 45500.0% | N/A | 3774.4% | 409.2% |
Balance Sheet
| Q1 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Assets | $579.1M | $754.8M | $701.4M | $729.9M | $791.6M |
| Liabilities | $10.2M | $21.4M | $31.1M | $42.3M | $39.0M |
| Equity | $568.9M | $733.4M | $670.4M | $687.6M | $752.6M |
Cash Flow
| Q1 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Operating CF | $-26.0M | $-20.7M | $-28.0M | $-38.9M | $-36.2M |